Concordance between Self-reported Symptoms and Clinically Ascertained Peripheral Neuropathy among Childhood Cancer Survivors: the St. Jude Lifetime Cohort Study.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
26
05
2021
revised:
30
07
2021
accepted:
13
09
2021
pubmed:
30
9
2021
medline:
5
3
2022
entrez:
29
9
2021
Statut:
ppublish
Résumé
Childhood cancer survivors are at elevated risk for motor and/or sensory neuropathy. The study aims to evaluate the concordance between self-report peripheral neuropathy compared with clinically ascertained peripheral neuropathy, and to identify factors associated with misclassification of peripheral neuropathy among survivors. The concordance between self-report and clinically ascertained peripheral neuropathy was evaluated among 2,933 5+ years old childhood cancer survivors (mean age 33.3, SD = 8.9). The sensitivity, specificity, and accuracy of self-report peripheral motor neuropathy (PMN) and peripheral sensory neuropathy (PSN) were calculated with reference to clinically assessed peripheral neuropathy. Female survivors were more likely than male survivors to have clinically ascertained PMN (8.4% vs. 5.6%, Agreement between self-report and clinically ascertained peripheral neuropathy was poor in survivors. Choosing self-report versus clinical ascertained peripheral neuropathy should be carefully considered. The current study identifies the need for a self-report questionnaire that accurately assesses symptoms of peripheral neuropathy among cancer survivors.
Sections du résumé
BACKGROUND
Childhood cancer survivors are at elevated risk for motor and/or sensory neuropathy. The study aims to evaluate the concordance between self-report peripheral neuropathy compared with clinically ascertained peripheral neuropathy, and to identify factors associated with misclassification of peripheral neuropathy among survivors.
METHODS
The concordance between self-report and clinically ascertained peripheral neuropathy was evaluated among 2,933 5+ years old childhood cancer survivors (mean age 33.3, SD = 8.9). The sensitivity, specificity, and accuracy of self-report peripheral motor neuropathy (PMN) and peripheral sensory neuropathy (PSN) were calculated with reference to clinically assessed peripheral neuropathy.
RESULTS
Female survivors were more likely than male survivors to have clinically ascertained PMN (8.4% vs. 5.6%,
CONCLUSIONS
Agreement between self-report and clinically ascertained peripheral neuropathy was poor in survivors. Choosing self-report versus clinical ascertained peripheral neuropathy should be carefully considered.
IMPACT
The current study identifies the need for a self-report questionnaire that accurately assesses symptoms of peripheral neuropathy among cancer survivors.
Identifiants
pubmed: 34583966
pii: 1055-9965.EPI-21-0644
doi: 10.1158/1055-9965.EPI-21-0644
pmc: PMC8643312
mid: NIHMS1745028
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2256-2267Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA195547
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Mayo Clin Proc. 2010 Mar;85(3 Suppl):S42-50
pubmed: 20194148
J Clin Oncol. 2013 Nov 20;31(33):4242-51
pubmed: 24127449
Psychooncology. 2019 Sep;28(9):1926-1933
pubmed: 31293046
Cancer Epidemiol Biomarkers Prev. 2021 Aug;30(8):1536-1545
pubmed: 34099519
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):53-59
pubmed: 29346338
JAMA Neurol. 2018 Aug 1;75(8):980-988
pubmed: 29799906
Breast Cancer Res Treat. 2011 Feb;125(3):767-74
pubmed: 21128110
Cancer Treat Rev. 2016 Nov;50:118-128
pubmed: 27664395
J Pain. 2009 Nov;10(11):1146-50
pubmed: 19595634
Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):666-674
pubmed: 28035022
Fam Med. 2005 May;37(5):360-3
pubmed: 15883903
Pediatr Blood Cancer. 2013 May;60(5):856-64
pubmed: 23024097
Support Care Cancer. 2016 Sep;24(9):3723-8
pubmed: 27037813
Support Care Cancer. 2014 Aug;22(8):2261-9
pubmed: 24789421
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Phys Ther. 2005 Aug;85(8):782-90
pubmed: 16048425
JAMA. 2013 Jun 12;309(22):2371-2381
pubmed: 23757085
Support Care Cancer. 2013 Jul;21(7):2059-66
pubmed: 23446880
J Clin Oncol. 2018 Aug 1;36(22):2315-2322
pubmed: 29812998
Pediatr Blood Cancer. 2011 May;56(5):825-36
pubmed: 21370418
Diabetes Care. 1993 Nov;16(11):1446-52
pubmed: 8299433
J Aging Health. 2000 May;12(2):229-49
pubmed: 11010698
Support Care Cancer. 2009 Dec;17(12):1483-91
pubmed: 19330359
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Am J Occup Ther. 1986 Oct;40(10):705-11
pubmed: 3777107
J Peripher Nerv Syst. 2007 Sep;12(3):210-5
pubmed: 17868248
Arch Phys Med Rehabil. 2013 Aug;94(8):1451-7
pubmed: 23537607
Pediatr Blood Cancer. 2014 Jan;61(1):46-52
pubmed: 24115507
Gerontology. 2006;52(6):345-52
pubmed: 16905886
Eur J Appl Physiol. 2012 Jan;112(1):267-75
pubmed: 21537927
J Am Geriatr Soc. 1990 Oct;38(10):1105-12
pubmed: 2229864
Breast Cancer Res Treat. 2021 Apr;186(3):761-768
pubmed: 33507480
Int J Epidemiol. 2021 Mar 3;50(1):39-49
pubmed: 33374007